Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-11-09 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 奥锐特药业股份有限公司. It details the meeting date, attendance, and voting results on various proposals related to the issuance of convertible bonds. The document references prior announcements and filings but itself is a notice of board decisions rather than a full report or financial statement. The content focuses on board meeting resolutions and governance matters, specifically changes and approvals by the board. The document length is 2753 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2023-11-09 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed proposal and explanatory note for a convertible bond issuance by 奥锐特药业股份有限公司. It includes extensive financial statements such as consolidated balance sheets, profit and loss statements, and cash flow statements, as well as management discussion and analysis related to the bond issuance. The document contains substantive financial data and analysis, not just an announcement or summary. It is not a simple announcement of a report publication, nor is it a certification or a transcript. The content focuses on capital raising through convertible bonds, including terms, conditions, and financial implications. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-11-09 Chinese
奥锐特药业股份有限公司第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the third Supervisory Board of 奥锐特药业股份有限公司. It details the meeting's procedural compliance, the voting results on various proposals related to the issuance of convertible bonds, and references other announcements published elsewhere for detailed content. The document is relatively short (2181 characters) and primarily serves as a meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed analysis but rather the outcomes of supervisory board decisions. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about corporate governance matters and bond issuance approvals without being a full report or financial disclosure.
2023-11-09 Chinese
奥锐特药业股份有限公司独立董事关于第三届董事会第四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's board meeting, specifically about revisions to the company's convertible bond issuance plans and related reports. It references compliance with regulatory rules and company bylaws, and provides independent opinions on various amendments to issuance proposals and analysis reports. The document is not a full financial report, earnings release, or annual report, but rather a formal opinion related to board decisions and regulatory compliance. It does not announce voting results, nor is it a proxy solicitation or remuneration report. The content aligns with Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on corporate governance and issuance plans. The document length is short (1633 characters), and it is not merely an announcement but contains substantive independent opinions. Therefore, the best classification is MANG with high confidence.
2023-11-09 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券方案的论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report discussing the issuance of convertible corporate bonds by 奥锐特药业股份有限公司, a Shanghai Stock Exchange listed company. It includes extensive information on the necessity of the issuance, the type of securities, pricing principles, legal and regulatory compliance, use of proceeds, and fairness of the issuance plan. The document references Chinese securities laws, regulatory requirements, and includes financial data and audit references. It is a comprehensive analysis and proposal report related to a capital raising activity through convertible bonds. This fits the definition of a Capital/Financing Update (CAP), as it provides an update on the company's financing activities and capital structure changes. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-11-09 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券募集资金使用可行性的分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for the use of funds raised through a convertible bond issuance by 奥锐特药业股份有限公司. It includes extensive information on the investment projects, their background, economic benefits, construction plans, and impact on the company's financial status. The document is not a financial report like an annual or interim report, nor is it an announcement of voting results or management changes. It is a capital/financing update related to the company's fundraising activities and the intended use of the raised capital. The length and detail confirm it is a substantive report, not a brief announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-11-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.